SPRY - ARS Pharmaceuticals, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
ARS Pharmaceuticals, Inc.
IPO Date: December 4, 2020
Sector: Healthcare
Industry: Biotech
Market Cap: $433.59M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.32 | 3.48%
Avg Daily Range (30 D): $0.17 | 3.34%
Avg Daily Range (90 D): $0.27 | 4.04%
Institutional Daily Volume
Avg Daily Volume: 1.13M
Avg Daily Volume (30 D): 1.22M
Avg Daily Volume (90 D): 1.59M
Trade Size
Avg Trade Size (Sh.): 91
Avg Trade Size (Sh.) (30 D): 102
Avg Trade Size (Sh.) (90 D): 101
Institutional Trades
Total Institutional Trades: 986
Avg Institutional Trade: $1.58M
Avg Institutional Trade (30 D): $.94M
Avg Institutional Trade (90 D): $1.37M
Avg Institutional Trade Volume: .15M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.75M
Avg Closing Trade (30 D): $.96M
Avg Closing Trade (90 D): $1.47M
Avg Closing Volume: 171.21K
 
News
Oct 2, 2026 @ 6:57 PM
ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVES...
Source: Rosen Law Firm
Oct 2, 2026 @ 6:43 PM
ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel ...
Source: Bragar Eagel & Squire, P.C.
Sep 29, 2026 @ 12:19 AM
ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVES...
Source: Rosen Law Firm
Sep 29, 2026 @ 12:11 AM
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Tig...
Source: Rosen Law Firm
Sep 24, 2026 @ 1:57 PM
SPRY Investors Have Opportunity to Lead ARS Pharma...
Source: Schall, Brown & Schwartz Llp
Financials
  TTM Q1 2026 Q4 2025
Basic EPS $-.63 $-.61 $-.42
Diluted EPS $-.63 $-.61 $-.42
Revenue $33.66M $22.68M $28.09M
Gross Profit
Net Income / Loss $-62.34M $-60.62M $-41.32M
Operating Income / Loss $-61.47M $-60.15M $-41.47M
Cost of Revenue
Net Cash Flow $-16.16M $-17M $-18.24M
PE Ratio